Top Markets
#1 MarsCoin MarsCoin +65.01%
#2 Palladium Network Palladium Network +53.21%
#3 Siren Siren +27.68%
#4 Useless Coin Useless Coin +26.44%
#5 Status Status +19.19%
#6 edgeX edgeX +18.30%
#7 Asteroid Shiba Asteroid Shiba +17.98%
#8 Bedrock Bedrock +17.10%
#9 PondCoin PondCoin +15.71%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
Coin of the day
MarsCoin MarsCoin
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Innate Pharma S.A. Innate Pharma S.A.

Innate Pharma S.A.

IPH
Rankning i aktier #18401
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Aktiekurs
$2.13
Senast synkroniserad: 2026-09-02
Marknadsvärde
$200.27M
Förändring (1 dag)
0.90%
Förändring (1 år)
-1.67%
Land
FR
Handel Innate Pharma S.A. (IPH)

Kategori

Healthcare
Aktiekurshistorik för Innate Pharma S.A. (IPH)
Högsta slutkurs: $2.13 den 2026-09-01

Lägsta slutkurs: $6.63 den 2006-11-01
Aktiekurshistorik för Innate Pharma S.A. från 2006 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) -3.21%
2025 3.04%
2024 -29.45%
2023 1.22%
2022 -47.82%
2021 5.57%
2020 -25.88%
2019 -27.85%
2018 56.37%
2017 -61.72%
2016 0.18%
2015 42.51%
2014 55.39%
2013 131.25%
2012 54.32%
2011 11.88%
2010 -54.81%
2009 93.03%
2008 -63.31%
2007 -30.89%
2006 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $556.43 40.29%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 45.39%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $152.82 535.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $123.39 -8.70%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $760.83 7.20%
CH